Sanofi
Q4 2022 Earnings Call
Feb 03, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Eva Schaefer-Jansen
May cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors. With that, please advance to Slide 4. Our speakers on the call today are Paul Hudson, chief executive officer; the Global business unit head, Bill Sibold; Thomas Triomphe; Olivier Charmeil; Julie van Ongevalle; and Jean-Baptiste de Chatillon, chief financial officer.
For the Q&A, you have two options to participate. Option 1, click the Raise Hand icon at the bottom of your screen, or, Option 2, submit your question by clicking the Q&A icon at the bottom of your screen. And with that, I'd like to turn the call over to Paul.
Paul Hudson -- Chief Executive Officer
Well, thank you, Eva. Nicely done, and thanks to everyone for joining our call today. I'm delighted to be here and together with members of the executive team to take you through our 2022 business and financial performance. We're proud of the progress we made in transforming our R&D organization while delivering on operational and financial performance.
With 10 consecutive quarters of growth, we are successfully closing the first chapter of our Play to Win strategy. And moving on to the next chapter. Well, we're looking forward to the upcoming launches, key readouts, as well as Dupixent that is set to reach 10 billion euros in 2023. On Slide 6, starting with the full-year view, 2022 marks the first year where specialty care delivered the highest sales among our businesses.
The main driver of this performance is Dupixent. This unique medicine, which we identified in 2019, is a core driver of our transformation. The biologic profile of Dupixent to this day, we believe, remains the best in its class with the exceptional ability to balance high efficacy with compelling safety. Blazing the trail in markets that are underpenetrated in terms of eligible patient populations, Dupixent keeps adding significant patient pools through multiple approvals and diseases that are still underserved.
Without question, this medicine that is now a key cornerstone in treating chronic type 2 inflammatory diseases. 2022 also marks another successful year for vaccines. We maintain our leadership in flu and are gaining momentum quickly as the pediatric vaccines company of choice. In fact, Thomas will share with you in a few minutes how well our latest pediatric launch is performing.